- Home
- UROY vs CATX Comparison
UROY vs CATX Comparison
Compare UROY & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | CATX |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.6M | 341.0M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UROY | CATX |
|---|---|---|
| Price | $4.14 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | ★ 3.5M | 1.2M |
| Earning Date | 03-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.51 | $1.96 |
| 52 Week High | $5.52 | $6.16 |
Technical Indicators
Market Signals| Indicator | UROY | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 73.94 | 50.50 |
| Support Level | $3.40 | $2.82 |
| Resistance Level | $4.48 | $4.27 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 91.37 | 73.47 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.